Use of metformin and aspirin is associated with delayed cancer incidence
| Autor: | Sarah Ty Yau, Jason M.W. Ho, Joseph J.Y. Sung, Amy S M Lam, Kelvin K.F. Tsoi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Delayed Diagnosis endocrine system diseases Epidemiology Rectum Gastroenterology 03 medical and health sciences 0302 clinical medicine Prostate Internal medicine Neoplasms medicine Humans 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over Aspirin Cancer prevention business.industry Incidence (epidemiology) Incidence Hazard ratio Cancer Middle Aged medicine.disease Metformin medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | Cancer epidemiology. 69 |
| ISSN: | 1877-783X |
| Popis: | Background While the chemoprevention effect of aspirin is well-established, the effects of metformin in cancer prevention is still controversial. This study is to investigate the use of aspirin, metformin, or the combination of both is associated with delayed cancer incidence. Method This dataset is based on the electronic medical record of public hospitals in Hong Kong. Patients were classified into 1. aspirin user, 2. metformin user, 3. both aspirin and metformin user and 4. control group with neither aspirin nor metformin used. Aspirin and/or metformin must have been taken for over 6 months in the treatment group and cancer incidences was counted at least 6 months after exposure to such medications. The primary outcome of this study was overall incidence of cancer during the follow-up period. The secondary outcomes were cancer incidences of specific sites, including colon/rectum, liver, oesophagus, pancreas, stomach, lung, breast, kidney, bladder and prostate. Cox proportional hazards regression models were fitted to estimate hazard ratios of cancer risks. Inverse probability of treatment weighting was used to control for the medication effects. Results A total of 120,971 aspirin users, 11,365 metformin users, and 6630 aspirin plus metformin users, were identified. Compare to the control groups, those who used aspirin alone demonstrated a significant reduction in overall cancer risk (HR 0.80, 95% CI 0.73-0.87). Similarly, those who used metformin alone also showed an overall reduction in cancer risk (HR 0.79, 95% CI 0.71-0.88). Patients who received both aspirin and metformin showed the most significant reduction in overall cancer risk (HR 0.53, 95% CI 0.45-0.63). Metformin showed a significant reduction in cancer risk of lung, oesophagus and bladder. Conclusion There is a similar decrease in overall cancer rate with the use of aspirin or metformin alone. A more significant reduction in overall cancer risk was found with the use of both agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect